AZAINDOLE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF

摘要

Provided herein are compounds of the formulas (I) and (II):;;as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of Retinoic Acid Receptor-Related Orphan Receptor regulated diseases and disorders.

主权项

1. A compound of formula (I):wherein:
A is a monocyclic or bicyclic 5- to 8-membered heterocyclic ring having one ring carbon replaced by N as shown, said ring optionally mono- or bi-substituted on one or more ring carbons independently with a C1-C6 alkyl group; X is —(CH2)n—, —O—, or —NH—; Y is —(CH2)p—, —O—, —S— or —SO2—, with the proviso that X and Y are not both a heteroatom; Z is —(CH2)q—; R1 is —C1-C6 alkyl, optionally substituted with one or more —OH, halogen or —CN,
phenyl, optionally mono- or bisubstituted independently with halogen, alkoxy, C1-C6 alkyl, —CN, alkylsulfonyloxy, alkylsulfonyl, halo-C1-C6 alkyl or C1-C5 cycloalkyl,cycloalkyl, optionally substituted,heterocycle, optionally substituted ora 5- or 6-membered heteroaryl group having one or more ring carbons independently replaced by N, O or S, said heteroaryl optionally mono- or bisubstituted independently with halogen, alkoxy, C1-C6 alkyl, —CN, nitrile or perfluorinated C1-C6 alkyl; R2 is a 5- to 7-membered heteroaryl group having one, two or three ring carbons independently replaced by N, O or S, said heteroaryl optionally mono- or bi-substituted independently with C1-C6 alkyl, —CN or (═O); n is 0 or 1; p is 0 or 1; and q is 0, 1 or 2,or a pharmaceutically acceptable salt thereof.